Motesanib (AMG-706)
分子式： C22H23N5O分子量：373.45
简介： Motesanib (AMG-706)是一种具有口服生物活性的受体酪氨酸激酶 (receptor tyrosine kinase)抑制剂，对VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR和Ret的IC50值分别为2、3、6、8、84和59 nM。
物理性状及指标：
外观：……………………粉末
溶解性：…………………H2O ：Insoluble；Ethanol：8 mg/mL (21.42 mM)；DMSO: 75 mg/mL (200.83 mM)
含量：……………………>98%
储存温度：-20℃，避光防潮密闭干燥
运输条件：2~8℃运输
生物活性
|
描述
|
Motesanib (AMG-706)是一种具有口服生物活性的受体酪氨酸激酶 (receptor tyrosine kinase)抑制剂，对VEGFR1, VEGFR2, VEGFR3, Kit, PDGFR和Ret的IC50值分别为2、3、6、8、84和59 nM。 |
|||||||||||
|
IC50 & Target |
|
|||||||||||
|
体外 |
Motesanib has broad activity against the human VEGFR family, and displays > 1000 selectivity against EGFR, Src, and p38 kinase. Motesanib significantly inhibits VEGF-induced cellular proliferation of HUVECs with an IC50 of 10 nM, while displaying little effect at bFGF-induced proliferation with an IC50 of >3,000 nM. Motesanib also potently inhibits PDGF-induced proliferation and SCF-induced c-kit phosphorylation with IC50 of 207 nM and 37 nM, respectively, but not effective against the EGF-induced EGFR phosphorylation and cell viability of A431 cells Althouth displaying little antiproliferative activity on cell growth of HUVECs alone, Motesanib treatment significantly sensitizes the cells to fractionated radiation. |
|||||||||||
|
体内 |
Motesanib (100 mg/kg) significantly inhibits VEGF-induced vascular permeability in a time-dependent manner. Oral administration of Motesanib twice daily or once daily potently inhibits, in a dose-dependent manner, VEGF-induced angiogenesis using the rat corneal model with ED50 of 2.1 mg/kg and 4.9 mg/kg, respectively. Motesanib induces a dose-dependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells. Motesanib in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma (HNSCC) xenograft models. Motesanib treatment also induces significant dose-dependent reductions in tumor growth and blood vessel density of MCF-7, MDA-MB-231, or Cal-51 xenografts, which can be markedly enhanced when combined with docetaxel or tamoxifen |
相关产品推荐 (更多相关靶点抑制剂请详询官网或客服)
|
MB1050
|
西地尼布;AZD2171 |
|
MB1226 |
Sorafenib tosylate |
|
MB1230 |
Sunitinib Malate |
储液配置及储存： 按表中溶解性配置；如溶解困难，可以通过快速搅拌，超声或温和加热（在45-60°C下水浴）。液体稳定性报道的很少，建议现配现用，如需储存，建议：-20℃1-3月；-80℃ 3-6月。
 |
1 mg |
5 mg |
10 mg |
|
1 mM |
2.6777 mL |
13.3887 mL |
26.7773 mL |
|
5 mM |
0.5355 mL |
2.6777 mL |
5.3555 mL |
|
10 mM |
0.2678 mL |
1.3389 mL |
2.6777 mL |
|
50 mM |
0.0536 mL |
0.2678 mL |
0.5355 mL |
【注意 】
●我司产品为非无菌包装，若用于细胞培养，请提前做预处理，除去热原细菌，否则会导致染菌。
●部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，以上数据仅供参考交流研究之用。
我司所售出产品仅供于科研研究用途（非临床科研研究），每次销售产品行为都适用于我司网上所列明的。